Krishnansu S. Tewari, MD of University of California, Irvine discusses the most recent results from the FOCUS trial, including the first interim analysis which evaluated the safety of the drug as well as early signs of efficacy. The trial is sponsored by Mateon Therapeutics in South San Francisco, CA This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
FOCUS Trial: First Interim Analysis
